Search Within

Amanda Rachel Copeland

Formats
  1. Meeting Abstract (19)
  2. Journal Article (6)
Groups
  1. Nursing (25)
  2. Center for Hematologic Malignancies (23)
  3. Department of Medicine (23)
  4. Executive Committee, Center for Hematologic Malignancies (23)
  5. Hematologic Malignancies, Division of (23)
  6. Lymphoma (23)

More Groups

People
  1. Anas Younes (23)
  2. Andrew Zelenetz (13)
  3. Connie Batlevi (12)
  4. John Gerecitano (12)
  5. Craig Moskowitz (11)
  6. Andrew Intlekofer (9)

More People

Years
  1. 2020 (1)
  2. 2018 (2)
  3. 2017 (5)
  4. 2016 (6)
  5. 2015 (5)
  6. 2014 (4)

More Years

Publications
  1. Blood (10)
  2. Haematologica (3)
  3. Hematological Oncology (2)
  4. Journal of Clinical Oncology (2)
  5. Blood Cancer Journal (1)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (10)
  2. Ferrata Storti Foundation (3)
  3. American Society of Clinical Oncology (2)
  4. Oncology Nursing Society (ONS) (2)
  5. Wiley Blackwell (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Phase 1 trial of CUDC-907, a novel, oral dual inhibitor of HDAC and Pi3k: Updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma
    Meeting Abstract

    Younes, A.; Berdeja, J.; Patel, M.; Kelly, K.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Wang, J.; Gong, L.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • ENGAGE-501: Phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Batlevi, C. L.; Kasamon, Y.; Bociek, R. G.; Lee, P.; Gore, L.; Copeland, A.; Sorensen, R.; Ordentlich, P.; Cruickshank, S.; Kunkel, L.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: An open-label, dose-escalation, phase 1 trial
    Journal Article

    Younes, A.; Berdeja, J. G.; Patel, M. R.; Flinn, I.; Gerecitano, J. F.; Neelapu, S. S.; Kelly, K. R.; Copeland, A. R.; Akins, A.; Clancy, M. S.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Distinctive genomic alterations in testicular diffuse large B cell lymphoma
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Wang, L.; Intlekofer, A. M.; Copeland, A. R.; Jungbluth, A. A.; Reiner, A.; Pichardo, J. D.; Gallagher, M.; Bouvier, N.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Phase 1 trial testing single agent CUDC-907, a novel, oral dual inhibitor of histone deacetylase (HDAC) and PI3K: Initial assessment of patients with relapsed or refractory (RR) diffuse large B-Cell lymphoma (DLBCL), including double expressor (DE) lymphoma
    Meeting Abstract

    Younes, A.; Berdeja, J. G.; Patel, M. R.; Kelly, K. R.; Flinn, I. W.; Gerecitano, J. F.; Neelapu, S. S.; Copeland, A. R.; Akins, A.; Clancy, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A phase 1 trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory or relapsed lymphoma and multiple myeloma
    Meeting Abstract

    Oki, Y.; Berdeja, J.; Patel, M.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Akins, A.; Clancy, M.; Viner, J.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma
    Meeting Abstract

    Berdeja, J. G.; Oki, Y.; Patel, M. R.; Copeland, A.; Flinn, I.; Neelapu, S. S.; Viner, J.; Wang, J.; Gerecitano, J. F.; Younes, A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies
    Meeting Abstract

    Ma, A. W.; Atoyan, R.; Younes, A.; Flinn, I. W.; Oki, Y.; Copeland, A.; Berdeja, J. G.; Laliberte, R.; Viner, J.; Samson, M. E. S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save